WO2024257023 - TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/257023
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055815
International Filing Date
14.06.2024
Title **
[English]
TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF
[French]
LIGANDS DE PSEUDOKINASE TYK2 ET LEURS UTILISATIONS
Applicants **
ALEMBIC PHARMACEUTICALS LIMITED
Inventors
KURHADE, Suresh
PRIYADARSHANI, Garima
SISODIYA, Shailendra
HALLE, Mahesh
KAPURE, Jeevak Sopanrao
KURIAPPAN, Jissy Akkarapattiakal
MALLIK, Sanchari Basu
TANDON, Amol
SUBRAMANIAM, Ganesan
IYER, Abishek Venkatasubramanian
Priority Data
202321040658
14.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5925 | |
| EPO | Filing, Examination, Granting | 107145 | |
| Japan | Filing, Examination, Granting | 4894 | |
| South Korea | Filing, Examination, Granting | 7819 | |
| USA | Filing, Examination, Granting | 26040 |
Total:
151,823
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are compounds of formula (A) that are useful in the modulation of inflammation and treating associated disorders by acting on TYK2 to cause TYK2-mediated signal transduction inhibition. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, an endocrine disorder, a neurological disorder, a proliferative disorder, or a disorder associated with transplantation.[French]
L'invention concerne des composés de formule A qui sont utiles dans la modulation de l'inflammation et le traitement de troubles associés par action sur TYK2 pour provoquer une inhibition de la transduction de signal médiée par TYK2. Dans certains modes de réalisation, le trouble médié par TYK2 est un trouble auto-immun, un trouble inflammatoire, un trouble endocrinien, un trouble neurologique, un trouble prolifératif ou un trouble associé à une transplantation.